1996 Nobel Prize in Physiology or Medicine — Doherty and Zinkernagel: T cells recognize only their own MHC-presented antigens

What you will learn in this article

This article explains how the mystery of how cytotoxic T cells (Tc cells) selectively attack only virus-infected cells was solved. In 1973, Australian immunologist Peter Doherty and Swiss visiting researcher Rolf Zinkernagel, who met at the Canberra John Curtin Medical Research Centre, discovered MHC restriction through experiments involving lymphocytic choriomeningitis virus (LCMV) infection: T cells only decide to attack if they receive two signals: their own MHC + foreign antigen. We will also explore how this discovery laid the groundwork for today's immune checkpoint inhibitors (pembrolizumab, nivolumab), CAR-T cell therapy, vaccine design, and understanding of autoimmune diseases.

A story different from common sense — T cells require dual authentication

The immune system has multiple layers of defense. Antibodies (mediated by B cells) bind to pathogens outside of cells and mark them, but when viruses have already entered cells, antibodies cannot reach them. At this point, a method is needed to eliminate infected pathogens within the cells.

The answer is cytotoxic T cells (Tc cells, CD8+ T cells). These cells attack and kill infected cells, thereby preventing the spread of the virus. However, there is a problem: Tc cells must only attack infected cells and not normal cells. How do they distinguish between infected and normal cells?

In 1973, Doherty and Zinkernagel made a crucial discovery in Canberra. Tc cells confirm two things simultaneously:

First, the signature of their own MHC class I molecule: The MHC class I protein on the surface of infected cells confirms whether it is self. If it is not their own MHC, they will not react.

Second, the foreign antigen payload on the MHC: They confirm whether an antigen fragment (peptide) derived from an infecting virus is present on their own MHC.

Only when both conditions are met do Tc cells recognize the cell as infected and attack. This discovery was later established as the concept of MHC restriction.

In terms of CS, this is similar to a two-factor authentication (2FA) system. Tc cells, as validators, trust only if both the signature (MHC self-signature) and payload (foreign antigen) are present. If either the signature or payload is missing, authentication fails. Both elements must be verified before an action (attack) is executed.

The sophistication of this system is remarkable. Infected cells place both their own protein fragments on their own MHC, but when infected, they also place viral proteins. Tc cells recognize the cell as a target only if they have a T cell receptor (TCR) that recognizes the virus-derived fragment. Each Tc cell has its own unique TCR and only recognizes specific antigen-MHC combinations (as discovered by Tonegawa in 1987).

The Zeitgeist — Genetic Engineering's Decisive Blow and Korea's Shift in Status

1996 was a year of decisive shifts in the world of biotechnology and Korea's national status.

In world history, on July 5th, the birth of Dolly the sheep — The Roslin Institute in Scotland created the first cloned mammal by implanting the nucleus of a somatic cell into an egg. The announcement was made the following year (February 1997), but the birth occurred in this year. It marked the beginning of a new era of cloning, regeneration, and medical applications. On November 5th, Clinton was re-elected. Palm Pilot (March) and ICQ Messenger (November) were symbolic products of personal computing and the internet. At Stanford, Sergey Brin and Larry Page began working on the Google project — the origin of search, advertising, and AI in the late 20th century.

In Korean history, on December 12th, Korea joined the OECD — a symbolic leap in national status as it entered the club of developed countries. On September 18th, the Gangneung submarine infiltration incident — a North Korean "Shark" class submarine ran aground, and its crew infiltrated the land, leading to a 55-day operation. It symbolized the ongoing conflict between North and South Korea even after the Cold War. In January, Seo Taiji and Boys announced their retirement, and in September, H.O.T. debuted — marking a generational shift in Korean popular music and the beginning of the K-pop industry.

In this year of transformation, the Nobel Committee recognized two individuals who had elucidated the fundamental recognition system of cellular immunity. In a year when nations and cultures were redefining their status, the sophisticated system by which the immune system recognizes self from non-self was recognized.

Peter Doherty and Rolf Zinkernagel — A Chance Encounter in Canberra

Peter C. Doherty (1940~) is an Australian immunologist. Born in Brisbane, Australia, he received a Bachelor of Veterinary Science (1962) and a Master of Science (1966) from the University of Queensland. He reportedly preferred literature and history but chose veterinary medicine due to financial circumstances. During his university years, he became interested in animal viral diseases, and in 1967, he went to study at the University of Edinburgh in Scotland, where he received a Ph.D. in 1970. From 1972, he worked as a researcher in the Microbiology Department at the John Curtin Medical Research Centre in Canberra, Australia. From 1982 to 1987, he was the Head of the Department of Experimental Pathology at the John Curtin Medical School, and from 1988, he was the Head of the Department of Immunology at the St. Jude Children's Research Hospital in Memphis, USA.

Doherty describes himself as a "non-conformist, someone who likes new ideas, who works in his own way, and who doesn't even consider competing with other scientists."

Rolf M. Zinkernagel (1944~) is a Swiss immunologist. He studied at the University of Basel's Medical School from 1962 to 1968 and received his Ph.D. in Experimental Medicine and Biochemistry in 1975. In 1973, he went to study at the John Curtin Medical Research Centre in Canberra, Australia, where he met Doherty and began their joint research. From 1979 to 1992, he was a professor at the University of Zurich, and from 1992, he has been the director of the Institute of Experimental Immunology at the University of Zurich.

The meeting of these two individuals was crucial to the Nobel Prize. Doherty had already been conducting LCMV research in Canberra, and their collaboration began when Zinkernagel joined as a visiting researcher. Two young researchers from different continents met in Oceania and made a discovery that large laboratories in Europe and the United States had overlooked.

The Decisive Experiment — LCMV and Demonstration of MHC Restriction

The experimental system they used was clear.

Mouse A is infected with LCMV. The body develops antiviral Tc cells, which attack infected cells and suppress the spread of the virus.

If the Tc cells are isolated and reacted with infected cells from another mouse B? The expectation is that the Tc cells will still recognize and attack the infected cells.

However, the result was that the Tc cells did not attack infected cells of a different genotype (different MHC). Tc cells only attacked infected cells of their own genotype (their own MHC).

This experiment was decisive. For Tc cells to react, the condition of an antigen on their own MHC is essential. That is, the T cell receptor recognizes not the antigen alone, but the complex of self-MHC + antigen. This established the concept of MHC restriction.

Subsequently, this concept was expanded to the understanding of different subsets of cytotoxic T cells (CD8+, recognizing class I MHC) and helper T cells (CD4+, recognizing class II MHC).

CS Framework — Dual Authentication and Certificate Verification

The MHC restriction system can be reconfigured in terms of CS as follows:

Cell = Service Instance: Each cell is a service with its own certificate (MHC).

MHC Class I = Self-Signed Certificate: Cells display their self-certificate (HLA-A, B, C, etc.) on their surface. This certificate is unique to each individual.

Antigen Presentation = Payload Display: Cells place fragments of proteins made within them (self-proteins + viral proteins when infected) on the MHC and display them.

Tc Cell = Dual Authentication Validator: The Tc cell's T cell receptor (TCR) and CD8 co-receptor validate together. The TCR recognizes the payload (antigen), and the CD8 recognizes the MHC class I signature.

MHC Restriction = Signature Trust Policy: Tc cells only trust certificates with the self-MHC signature. They ignore those with different MHC.

Simultaneous Authentication Required = Two Conditions AND: if (self_MHC && foreign_antigen) then attack else ignore. If only self-MHC is present and the antigen is self, it is recognized as a normal cell and ignored. If self-MHC + foreign antigen is present, it is recognized as an infected cell and attacked.

Virus Evasion = Attack on Authentication System:

• MHC Class I Downregulation: Some viruses (HIV, HCMV) suppress the expression of MHC class I on infected cells → evading Tc cell recognition. However, this exposes them to natural killer (NK) cells.
• Antigen Variation: Influenza and other viruses continue to mutate their spike proteins to evade Tc cell recognition.

Cancer Cell Evasion = Certificate Forgery: Some cancer cells also downregulate MHC class I to evade Tc cell recognition. This is coupled with PD-1/PD-L1 immune checkpoints and forms a basic axis of tumor immune evasion.

Immune Checkpoint Inhibitors = Invalidating Authentication Bypass: Pembrolizumab (Keytruda) and nivolumab (Opdivo) block PD-1, allowing Tc cells to attack tumor cells. The fundamental principle of the 2018 Allison and Honjo Nobel Prize.

CAR-T = Injecting Custom Authentication Rules: Patient's T cells are engineered to insert artificial receptors that react to specific tumor targets (CD19, etc.). T cells are modified to attack targets regardless of MHC.

This analogy is not perfect. The actual immune response integrates multiple signals simultaneously (co-stimulatory signals, etc.), and MHC restriction is established early in T cell development (positive and negative selection in the thymus). It is a much more sophisticated system than simple dual authentication.

Academic Impact — The Era of Tumor Immunotherapy

Since this discovery, the fields of oncology, infectious disease, and transplantation have been fundamentally reorganized.

Era of Immune Checkpoint Inhibitors:

• Ipilimumab (Yervoy, 2011) — First approval of CTLA-4 inhibitor
• Nivolumab (Opdivo, 2014) and Pembrolizumab (Keytruda, 2014) — PD-1 inhibitors
• Atezolizumab (2016) and Durvalumab (2017) — PD-L1 inhibitors
• 2018 Allison and Honjo Nobel Prize in Physiology or Medicine — For the development of immune checkpoint inhibitors

CAR-T Cell Therapy:

• Kymriah (2017) — First FDA-approved CAR-T, for pediatric acute lymphoblastic leukemia
• Yescarta (2017) — For diffuse large B-cell lymphoma
• Tecartus (2020), Breyanzi (2021), Abecma (2021) — For various hematologic cancers

Vaccine Design: The concept of MHC restriction is fundamental to vaccine design. Epitope prediction algorithms are used to select antigen fragments that bind well to specific MHC alleles. This principle is also used in the design of COVID-19 vaccines.

Understanding Autoimmune Diseases: The event of self-antigens being presented on self-MHC and recognized by T cells is the basis of autoimmune diseases. Pathogenesis of diseases such as multiple sclerosis, type 1 diabetes, and rheumatoid arthritis.

Graft Rejection: Different MHCs of the transplanted organ elicit a strong response from the recipient's T cells. HLA matching determines the success rate of transplantation.

Korea's Legacy and Today

Korea's impact from this legacy is widespread. Since the late 1990s, research on T cells and MHC has been active in immunology laboratories at Seoul National University, Yonsei University, and KAIST.

Clinical Applications: At Seoul Asan Hospital, Samsung Seoul Hospital, Seoul National University Hospital, and Yonsei Severance Hospital, immune checkpoint inhibitors (pembrolizumab, nivolumab, etc.) are prescribed as standard treatment for lung cancer, melanoma, liver cancer, and gastric cancer. CAR-T cell therapy (Kymriah, introduced in Korea in 2021) has also begun. HLA testing is a standard procedure for all transplantation patients in university hospitals across the country.

Research on Korean HLA Polymorphism: At Seoul National University and Asan Medical Center, active research is being conducted on Korean-specific HLA alleles and their association with various autoimmune diseases and susceptibility to infection.

Why is it important?

What the two researchers established is that "cellular immunity is a dual authentication system that verifies the payload on top of a self-certificate."

This discovery fundamentally reshaped our understanding of the immune system. Before, it was not fully understood how T cells recognize their targets, but after the establishment of the MHC restriction concept, T cell biology developed in a sophisticated way.

The power of a chance encounter – Doherty and Zinkernagel's collaboration in Canberra is a prime example of international academic mobility. Two young researchers from different continents met in Oceania and made a discovery that large laboratories in Europe and the United States had missed.

Australia's scientific rise to the top – The fact that the John Curtin School of Medical Research at the Australian National University was the stage for this discovery is also symbolic. It shows that the center of world science is not limited to Western powers.

After this award, the flow of cellular immunity and tumor immunity continued as follows:

• 2011, Beutler, Hoffmann, and Steinman – Innate immunity, dendritic cells
• 2018, Allison and Honjo – Immune checkpoint inhibitors (CTLA-4, PD-1)

Clinical applications of this discovery:

• Immune checkpoint inhibitors: Pembrolizumab, Nivolumab, Ipilimumab, etc.
• CAR-T cell therapy: Kymriah, Yescarta, etc.
• Vaccine design: Epitope-based precision vaccines
• Diagnosis and treatment of autoimmune diseases: Related to HLA-B27, HLA-DR, etc.

→ Previous: 1995 – Lewis, Nüsslein-Volhard, Wieschaus → Next: [1997 – Batch 8 in progress]